Medif

Medif is evaluating a new PCSK9 inhibitor to lower the risk of heart attacks and strokes in adults who have not yet experienced these events. Another study examines the benefit of combining vicadrostat with empagliflozin to prevent cardiovascular death in patients with type 2 diabetes, high blood pressure, and established heart disease.

• PCSK9 inhibition for primary cardiovascular prevention
• Combination therapy with vicadrostat and empagliflozin
• Long‑term safety of lipid‑lowering agents

The site in Thuin, Belgium, conducts these trials with four investigators and collaborates with commercial partners.

The facility is testing an anti‑inflammatory antibody called astegolimab to reduce COPD exacerbations. A novel viral‑like particle vaccine containing RSV and hMPV antigens is being evaluated to protect seniors from lower respiratory infections. Additionally, a 21‑valent pneumococcal conjugate vaccine is studied in infants to improve protection against bacterial pneumonia.

• Astegolimab for COPD flare reduction
• RSV/hMPV VLP vaccine in older adults
• Pneumococcal conjugate vaccine in infants
• Assessment of pneumococcal immunization efficacy

Participants range from toddlers to adults over 60, reflecting the broad impact of respiratory diseases.

A new chickenpox vaccine is being compared with the licensed product to confirm seroresponse rates in toddlers. An RSV pre‑seasonal revaccination study measures the humoral immune response after a single booster dose.

• Varicella zoster vaccine lot consistency
• RSV preF3 OA revaccination immunogenicity
• Immunogenicity of RSV/hMPV VLP vaccine
• Safety monitoring of viral vaccines

These investigations support vaccine development for common viral infections across age groups.

Researchers are assessing the impact of ploazasiran on fasting triglyceride levels in adults with severe hypertriglyceridemia. A trial examines the effect of a combined regimen on time to first cardiovascular death in patients with type 2 diabetes, hypertension, and existing heart disease.

• Plozasiran for triglyceride reduction
• Combination therapy for diabetes‑related cardiovascular risk
• Long‑term safety of triglyceride‑lowering agents
• Evaluation of metabolic risk markers

The metabolic studies aim to improve outcomes for patients with elevated lipid levels and diabetes.

The site evaluates a 21‑valent pneumococcal conjugate vaccine to protect infants from invasive bacterial disease. A study monitors the immune response after pneumococcal immunization in adults at risk for respiratory infections.

• Pneumococcal vaccine efficacy in infants
• Immunogenicity of pneumococcal vaccination in adults
• Safety of multi‑valent bacterial vaccines

These trials address the burden of bacterial pneumonia and related complications.

Across multiple programs, Medif measures seroresponse rates and antibody concentrations to gauge vaccine performance. The laboratory also investigates immune system markers related to bacterial and viral challenges.

• Evaluation of seroresponse in varicella vaccine
• Assessment of IgG responses to pneumococcal conjugate
• Monitoring of immune biomarkers in RSV studies
• Cross‑reactivity analyses of vaccine‑induced immunity

Insights from these studies help optimize immunogenicity across the site’s diverse trial portfolio.